236 related articles for article (PubMed ID: 20795788)
41. Therapeutic implications of variable expression of CD52 on clonal cytotoxic T cells in CD8+ large granular lymphocyte leukemia.
Mohan SR; Clemente MJ; Afable M; Cazzolli HN; Bejanyan N; Wlodarski MW; Lichtin AE; Maciejewski JP
Haematologica; 2009 Oct; 94(10):1407-14. PubMed ID: 19794084
[TBL] [Abstract][Full Text] [Related]
42. Identifying alemtuzumab as an anti-myeloid cell antiangiogenic therapy for the treatment of ovarian cancer.
Pulaski HL; Spahlinger G; Silva IA; McLean K; Kueck AS; Reynolds RK; Coukos G; Conejo-Garcia JR; Buckanovich RJ
J Transl Med; 2009 Jun; 7():49. PubMed ID: 19545375
[TBL] [Abstract][Full Text] [Related]
43. Alemtuzumab for relapsed and refractory erythrodermic cutaneous T-cell lymphoma: a single institution experience from the Robert H. Lurie Comprehensive Cancer Center.
Querfeld C; Mehta N; Rosen ST; Guitart J; Rademaker A; Gerami P; Kuzel TM
Leuk Lymphoma; 2009 Dec; 50(12):1969-76. PubMed ID: 19860617
[TBL] [Abstract][Full Text] [Related]
44. A pilot trial of rituximab and alemtuzumab combination therapy in patients with relapsed and/or refractory chronic lymphocytic leukemia (CLL).
Nabhan C; Patton D; Gordon LI; Riley MB; Kuzel T; Tallman MS; Rosen ST
Leuk Lymphoma; 2004 Nov; 45(11):2269-73. PubMed ID: 15512816
[TBL] [Abstract][Full Text] [Related]
45. Monoclonal anti-CD52 antibodies: a potential mode of therapy for parvovirus B(19) hepatitis.
Granot E; Miskin H; Aker M
Transplant Proc; 2001 May; 33(3):2151-3. PubMed ID: 11377483
[No Abstract] [Full Text] [Related]
46. Involvement of neutrophils and natural killer cells in the anti-tumor activity of alemtuzumab in xenograft tumor models.
Siders WM; Shields J; Garron C; Hu Y; Boutin P; Shankara S; Weber W; Roberts B; Kaplan JM
Leuk Lymphoma; 2010 Jul; 51(7):1293-304. PubMed ID: 20377308
[TBL] [Abstract][Full Text] [Related]
47. Novel therapies for hypereosinophilic syndromes.
Antoniu SA
Neth J Med; 2010 Aug; 68(1):304-10. PubMed ID: 20739727
[TBL] [Abstract][Full Text] [Related]
48. Neuropathy associated with angioimmunoblastic lymphadenopathy-like T-cell lymphoma.
Sonobe M; Yasuda H; Okabe H; Terada M; Maeda K; Kawabata T; Kikkawa R
Intern Med; 1998 Jul; 37(7):631-4. PubMed ID: 9711895
[TBL] [Abstract][Full Text] [Related]
49. Alemtuzumab in T-cell lymphoproliferative disorders.
Dearden CE; Matutes E
Best Pract Res Clin Haematol; 2006; 19(4):795-810. PubMed ID: 16997184
[TBL] [Abstract][Full Text] [Related]
50. Alemtuzumab in solid organ transplantation and in composite tissue allotransplantation.
Weissenbacher A; Boesmueller C; Brandacher G; Oellinger R; Pratschke J; Schneeberger S
Immunotherapy; 2010 Nov; 2(6):783-90. PubMed ID: 21091110
[TBL] [Abstract][Full Text] [Related]
51. Alemtuzumab as treatment for residual disease after chemotherapy in patients with chronic lymphocytic leukemia.
O'Brien SM; Kantarjian HM; Thomas DA; Cortes J; Giles FJ; Wierda WG; Koller CA; Ferrajoli A; Browning M; Lerner S; Albitar M; Keating MJ
Cancer; 2003 Dec; 98(12):2657-63. PubMed ID: 14669286
[TBL] [Abstract][Full Text] [Related]
52. Treatment of FIP1L1/PDGFRA-negative hypereosinophilic syndrome with alemtuzumab, an anti-CD52 antibody.
Wagner LA; Speckart S; Cutter B; Gleich GJ
J Allergy Clin Immunol; 2009 Jun; 123(6):1407-8. PubMed ID: 19342084
[No Abstract] [Full Text] [Related]
53. Novel antibody approaches for T-cell lymphomas.
Goodman OB; Dang NH
Clin Lymphoma Myeloma; 2008 Dec; 8 Suppl 5():S193-8. PubMed ID: 19073527
[TBL] [Abstract][Full Text] [Related]
54. The role of alemtuzumab in the management of T-cell malignancies.
Dearden C
Semin Oncol; 2006 Apr; 33(2 Suppl 5):S44-52. PubMed ID: 16720203
[TBL] [Abstract][Full Text] [Related]
55. CD52 expression patterns in myeloma and the applicability of alemtuzumab therapy.
Rawstron AC; Laycock-Brown G; Hale G; Davies FE; Morgan GJ; Child JA; Hillmen P; Owen RG
Haematologica; 2006 Nov; 91(11):1577-8. PubMed ID: 17043027
[TBL] [Abstract][Full Text] [Related]
56. Alemtuzumab (Compath) off-label for relapsing multiple sclerosis.
Med Lett Drugs Ther; 2009 Mar; 51(1307):17-8. PubMed ID: 19265776
[No Abstract] [Full Text] [Related]
57. A mechanistic rationale for combining alemtuzumab and rituximab in the treatment of ALL.
Nijmeijer BA; van Schie ML; Halkes CJ; Griffioen M; Willemze R; Falkenburg JH
Blood; 2010 Dec; 116(26):5930-40. PubMed ID: 20844239
[TBL] [Abstract][Full Text] [Related]
58. Single-agent lenalidomide is effective in the treatment of a heavily pretreated and refractory angioimmunoblastic T-cell lymphoma patient.
Broccoli A; Pellegrini C; Celli M; Argnani L; Agostinelli C; Pileri S; Zinzani PL
Clin Lymphoma Myeloma Leuk; 2014 Aug; 14(4):e119-22. PubMed ID: 24629851
[No Abstract] [Full Text] [Related]
59. Advances in the use of alemtuzumab in CLL.
Stilgenbauer S
Clin Adv Hematol Oncol; 2008 Jan; 6(1):23-4. PubMed ID: 18322437
[No Abstract] [Full Text] [Related]
60. Guillain-Barré syndrome after use of alemtuzumab (Campath) in a patient with T-cell prolymphocytic leukemia: a case report and review of the literature.
Abbi KK; Rizvi SM; Sivik J; Thyagarajan S; Loughran T; Drabick JJ
Leuk Res; 2010 Jul; 34(7):e154-6. PubMed ID: 20362332
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]